Loading...
•
Dec 31, 2024
United Therapeutics Q4 2024 Earnings Report
United Therapeutics reported record revenue growth driven by strong performance across its product portfolio for Q4 2024.
Key Takeaways
United Therapeutics reported Q4 2024 revenue of $735.9 million, driven by significant growth in Tyvaso and Orenitram. The company achieved net income of $301.3 million and an EPS of $6.74. Adjusted EPS was $6.19. Strong performance across key product lines contributed to a robust quarter.
Total revenue for Q4 2024 was $735.9 million, up 20% from Q4 2023.
Net income for the quarter was $301.3 million.
Tyvaso revenue grew 19% to $415.9 million in Q4 2024.
EPS for the quarter was $6.74, and adjusted EPS was $6.19.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics expects continued revenue growth driven by strong product performance and pipeline development.
Positive Outlook
- Strong momentum in Tyvaso product line.
- Expansion of clinical trials for pipeline products.
- Growth in new patient starts for treprostinil products.
- Continued revenue growth anticipated from pipeline assets.
- Focus on product innovations and technology advancements.
Challenges Ahead
- Potential cost pressures due to inflation.
- Increased litigation expenses impacting profitability.
- Risks associated with regulatory delays.
- Ongoing competition in pulmonary hypertension market.
- R&D expenses expected to remain elevated.
Revenue & Expenses
Visualization of income flow from segment revenue to net income